• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prevalence of Fabry disease-causing variants in the UK Biobank.英国生物库中致 Fabry 病变异体的流行率。
J Med Genet. 2023 Apr;60(4):391-396. doi: 10.1136/jmg-2022-108523. Epub 2022 Aug 17.
2
Use of a rare disease registry for establishing phenotypic classification of previously unassigned variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup.利用罕见病登记处对先前未分配的变异体进行表型分类:多学科法布里病基因型-表型工作组的共识分类系统。
J Med Genet. 2020 Aug;57(8):542-551. doi: 10.1136/jmedgenet-2019-106467. Epub 2020 Mar 11.
3
Fabry Disease: prevalence of affected males and heterozygotes with pathogenic mutations identified by screening renal, cardiac and stroke clinics, 1995-2017.法布里病:1995 年至 2017 年通过对肾脏、心脏和中风诊所进行筛查,确定了受影响男性和携带致病性突变的杂合子的患病率。
J Med Genet. 2018 Apr;55(4):261-268. doi: 10.1136/jmedgenet-2017-105080. Epub 2018 Jan 12.
4
Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.在年轻的急性脑卒中患者中 Fabry 病和 GLA 变异体的流行情况:扩大筛查范围的挑战。意大利 Fabry 脑卒中登记研究。
J Neurol Sci. 2024 Feb 15;457:122905. doi: 10.1016/j.jns.2024.122905. Epub 2024 Jan 24.
5
Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients.干血斑中 GLA 变异体与α-半乳糖苷酶 A 谱的相关性:巴西患者的观察性研究。
Orphanet J Rare Dis. 2020 Jan 29;15(1):30. doi: 10.1186/s13023-019-1274-3.
6
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.在一项针对年轻卒中患者的大型法布里病筛查项目中鉴定出的α-半乳糖苷酶A基因突变的表型特征。
Clin Neurol Neurosurg. 2013 Jul;115(7):1088-93. doi: 10.1016/j.clineuro.2012.11.003. Epub 2012 Dec 4.
7
Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.通过全国性调查对韩国法布里病患者中GLA的临床特征和突变谱进行研究:迟发型表型的诊断不足
Medicine (Baltimore). 2017 Jul;96(29):e7387. doi: 10.1097/MD.0000000000007387.
8
The Identification of a Novel Pathogenic Variant of the Gene Associated with a Classic Phenotype of Anderson-Fabry Disease: A Clinical and Molecular Study.与经典型安德森-法布里病表型相关基因的新型致病变异的鉴定:一项临床与分子研究
Int J Mol Sci. 2025 Jan 8;26(2):470. doi: 10.3390/ijms26020470.
9
Newborn screening for Fabry disease in the north-west of Spain.西班牙西北部法布里病的新生儿筛查。
Eur J Pediatr. 2017 Aug;176(8):1075-1081. doi: 10.1007/s00431-017-2950-8. Epub 2017 Jun 23.
10
Impact of Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies.变异分类对法布里病估计患病率的影响:筛查研究的系统评价和荟萃分析。
Circ Genom Precis Med. 2023 Dec;16(6):e004252. doi: 10.1161/CIRCGEN.123.004252. Epub 2023 Dec 4.

引用本文的文献

1
Is Fabry disease more prevalent than we think? Understanding the critical role of family screening can make all the difference.法布里病是否比我们想象的更普遍?了解家族筛查的关键作用可能会带来截然不同的结果。
Int Urol Nephrol. 2025 Sep 13. doi: 10.1007/s11255-025-04717-6.
2
A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta.一项多国时间与动作研究,旨在描述使用阿加糖酶α和阿加糖酶β进行酶替代疗法治疗法布里病的体验和负担。
Orphanet J Rare Dis. 2025 Aug 11;20(1):419. doi: 10.1186/s13023-025-03707-2.
3
Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout () and Symptomatic (G3S) Murine Models.AAV8和AAV9基因疗法在法布里敲除()和有症状(G3S)小鼠模型中的比较评估。
Genes (Basel). 2025 Jun 29;16(7):766. doi: 10.3390/genes16070766.
4
Incidental Identification of Potentially Affected Individuals Through Expanded Carrier Screening During Preconception or Early Pregnancy.在孕前或孕早期通过扩大携带者筛查偶然发现可能受影响的个体。
Prenat Diagn. 2025 Aug;45(9):1151-1159. doi: 10.1002/pd.6859. Epub 2025 Jul 18.
5
Case Series: Genetic mimics of hypertrophic cardiomyopathy in elderly.病例系列:老年人肥厚型心肌病的遗传模拟物
Front Cardiovasc Med. 2025 Jun 12;12:1483390. doi: 10.3389/fcvm.2025.1483390. eCollection 2025.
6
Early Atrial Remodeling Drives Arrhythmia in Fabry Disease.早期心房重构促使法布里病发生心律失常。
Circ Arrhythm Electrophysiol. 2025 Jul;18(7):e013352. doi: 10.1161/CIRCEP.124.013352. Epub 2025 Jun 25.
7
Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre.法布里病成年患者的真实世界临床结局:一项来自单一中心的20年回顾性观察队列研究。
Mol Genet Metab Rep. 2025 May 14;43:101229. doi: 10.1016/j.ymgmr.2025.101229. eCollection 2025 Jun.
8
Current status of the immunogenicity of enzyme replacement therapy in fabry disease.法布里病酶替代疗法的免疫原性现状
Orphanet J Rare Dis. 2025 May 26;20(1):253. doi: 10.1186/s13023-025-03705-4.
9
Medically Actionable Secondary Findings from Whole-Exome Sequencing (WES) Data in a Sample of 3972 Individuals.对3972名个体样本的全外显子组测序(WES)数据进行的具有医学可操作性的次要发现
Int J Mol Sci. 2025 Apr 9;26(8):3509. doi: 10.3390/ijms26083509.
10
Progress and Challenges in the Treatment of Fabry Disease.法布里病治疗的进展与挑战
BioDrugs. 2025 May 1. doi: 10.1007/s40259-025-00723-3.

本文引用的文献

1
Screening for Fabry disease in male patients with end-stage renal disease in western France.法国西部终末期肾病男性患者中 Fabry 病的筛查。
Nephrol Ther. 2021 Jun;17(3):180-184. doi: 10.1016/j.nephro.2021.03.002. Epub 2021 May 11.
2
Identification of patients with Fabry disease using routine pathology results: PATHFINDER (eGFR) study.使用常规病理结果鉴定法布里病患者:PATHFINDER(eGFR)研究。
Int J Clin Pract. 2021 Feb;75(2):e13672. doi: 10.1111/ijcp.13672. Epub 2020 Sep 7.
3
The mutational constraint spectrum quantified from variation in 141,456 humans.从 141456 名人类个体的变异中量化的突变约束谱。
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
4
Two related Chinese Fabry disease patients with a p.N215S pathological variant who presented with nephropathy.两名携带p.N215S病理变异且患有肾病的相关中国法布里病患者。
Mol Genet Metab Rep. 2020 May 15;24:100596. doi: 10.1016/j.ymgmr.2020.100596. eCollection 2020 Sep.
5
A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.男性和女性法布里病诊断的综合检测算法。
Mol Genet Metab. 2020 Jul;130(3):209-214. doi: 10.1016/j.ymgme.2020.04.006. Epub 2020 May 3.
6
Newborn screening for Fabry disease in the western region of Japan.日本西部地区法布里病的新生儿筛查。
Mol Genet Metab Rep. 2020 Jan 11;22:100562. doi: 10.1016/j.ymgmr.2019.100562. eCollection 2020 Mar.
7
Diagnostic strategy for females suspected of Fabry disease.疑似法布里病女性的诊断策略。
Clin Genet. 2020 Apr;97(4):655-660. doi: 10.1111/cge.13694. Epub 2020 Jan 7.
8
Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting.在人群环境中评估疑似致病变异的致病性、外显率和表现度。
Am J Hum Genet. 2019 Feb 7;104(2):275-286. doi: 10.1016/j.ajhg.2018.12.015. Epub 2019 Jan 18.
9
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?GLA 基因突变与溶酶体β-半乳糖苷酶:真的是安德森-法布里病吗?
Int J Mol Sci. 2018 Nov 23;19(12):3726. doi: 10.3390/ijms19123726.
10
The UK Biobank resource with deep phenotyping and genomic data.英国生物银行资源库,具有深度表型和基因组数据。
Nature. 2018 Oct;562(7726):203-209. doi: 10.1038/s41586-018-0579-z. Epub 2018 Oct 10.

英国生物库中致 Fabry 病变异体的流行率。

Prevalence of Fabry disease-causing variants in the UK Biobank.

机构信息

College of Medicine and Health, University of Exeter Medical School, Exeter, UK

College of Medicine and Health, University of Exeter, Exeter, UK.

出版信息

J Med Genet. 2023 Apr;60(4):391-396. doi: 10.1136/jmg-2022-108523. Epub 2022 Aug 17.

DOI:10.1136/jmg-2022-108523
PMID:35977816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10086508/
Abstract

BACKGROUND

Fabry disease is an X-linked lysosomal storage disorder resulting from deficiency of the alpha-galactosidase A enzyme leading to accumulation of globotriaosylceramide in multiple organ sites with prominent cardiovascular and renal involvement. Global prevalence estimates of Fabry disease based on clinical ascertainment range from 1 in 40 000 to 1 in 170 000. We aimed to determine the prevalence of Fabry disease-causing variants in UK Biobank.

METHODS

We sought gene variants in exome sequencing data from 200 643 individuals from UK Biobank. We used ACMG/AMP guidelines (American College of Medical Genetics/Association for Molecular Pathology) to classify pathogenicity and compared baseline biomarker data, hospital ICD-10 (International Classification of Diseases version-10) codes, general practitioner records and self-reported health data with those without pathogenic variants.

RESULTS

We identified 81 coding variants. We identified eight likely pathogenic variants on the basis of being rare (<1/10 000 individuals) and either previously reported to cause Fabry disease, or being protein-truncating variants. Thirty-six individuals carried one of these variants. In the UK Biobank, the prevalence of likely pathogenic Fabry disease-causing variants is 1/5732 for late-onset disease-causing variants and 1/200 643 for variants causing classic Fabry disease.

CONCLUSION

Fabry disease-causing variants are more prevalent in an unselected population sample than the reported prevalence of Fabry disease. These are overwhelmingly variants associated with later onset. It is possible the prevalence of later-onset Fabry disease exceeds current estimates.

摘要

背景

法布瑞病是一种 X 连锁溶酶体贮积病,由α-半乳糖苷酶 A 缺乏引起,导致糖鞘脂在多个器官部位堆积,主要累及心血管和肾脏。基于临床确诊的法布瑞病全球患病率估计值为每 40000 至 170000 人中有 1 例。我们旨在确定英国生物银行中法布瑞病致病变异的患病率。

方法

我们在英国生物银行的 200643 名个体的外显子组测序数据中寻找基因变异。我们使用 ACMG/AMP 指南(美国医学遗传学学院/分子病理学协会)对致病性进行分类,并将基线生物标志物数据、医院 ICD-10(国际疾病分类第 10 版)代码、全科医生记录和自我报告的健康数据与无致病性变异的个体进行比较。

结果

我们确定了 81 个编码变异。我们根据罕见性(<1/10000 个体)和是否先前报道过引起法布瑞病或是否为蛋白截断变异,将八种可能的致病性变异归类为致病性变异。36 名个体携带其中一种变异。在英国生物银行中,晚发型法布瑞病致病变异的患病率为每 5732 例中 1 例,经典法布瑞病致病变异的患病率为每 200643 例中 1 例。

结论

在未选择的人群样本中,法布瑞病致病变异的患病率高于报道的法布瑞病患病率。这些变异绝大多数与晚发型疾病相关。晚发型法布瑞病的患病率可能超过目前的估计。